Showing results (171-180 of 193) with videos related to
Sort By:
Pageof 20
The New England Journal of Medicine|December 5, 2008
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferonAdrian M Di Bisceglie, Mitchell L Shiffman, Gregory T Everson, et al.Hepatology (Baltimore, Md.)|June 30, 2005
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohortAnna S F Lok, Marc G Ghany, Zachary D Goodman, et al.Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 1, 2015
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research networkRobert S Brown, Jacqueline G O'Leary, K Rajender Reddy, et al.Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.Hepatology (Baltimore, Md.)|August 14, 2009
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis CNeal D Freedman, James E Everhart, Karen L Lindsay, et al.Journal of Hepatology|September 2, 2005
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie, Richard K Sterling, Raymond T Chung, et al.Drug Safety|November 3, 2020
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisWilliam R Treem, Melissa Palmer, Isabelle Lonjon-Domanec, et al.Gastroenterology|March 25, 2014
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infectionAdrian M Di Bisceglie, Ewa Janczweska-Kazek, François Habersetzer, et al.Pageof 20